Literature DB >> 33576238

Association of Mast Cell Burden and TIM-3 Expression with Recalcitrant Chronic Rhinosinusitis with Nasal Polyps.

Michael A Belsky1, Erica Corredera1, Hridesh Banerjee2, John Moore3, Li Wang4, Lawrence P Kane2, Stella E Lee3.   

Abstract

OBJECTIVES: Previous work showed that higher polyp mast cell load correlated with worse postoperative endoscopic appearance in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Polyp epithelial mast cells showed increased expression of T-cell/transmembrane immunoglobulin and mucin domain protein 3 (TIM-3), a receptor that promotes mast cell activation and cytokine production. In this study, CRSwNP patients were followed post-operatively to investigate whether mast cell burden or TIM-3 expression among mast cells can predict recalcitrant disease.
METHODS: Nasal polyp specimens were obtained via functional endoscopic sinus surgery (FESS) and separated into epithelial and stromal layers via enzymatic digestion. Mast cells and TIM-3-expressing mast cells were identified via flow cytometry. Mann-Whitney U tests and Cox proportional hazard models assessed whether mast cell burden and TIM-3 expression were associated with clinical outcomes, including earlier recurrence of polypoid edema and need for treatment with steroids.
RESULTS: Twenty-three patients with CRSwNP were studied and followed for 6 months after undergoing FESS. Higher mast cell levels were associated with earlier recurrence of polypoid edema: epithelial HR = 1.283 (P = .02), stromal HR = 1.103 (P = .02). Percent of mast cells expressing TIM-3 in epithelial or stromal layers was not significantly associated with earlier recurrence of polypoid edema. Mast cell burden and TIM-3+ expression were not significantly associated with need for future treatment with steroids post-FESS.
CONCLUSIONS: Mast cell load in polyp epithelium and stroma may predict a more refractory postoperative course for CRSwNP patients. The role of TIM-3 in the chronic inflammatory state seen in CRSwNP remains unclear.

Entities:  

Keywords:  TIM-3; chronic rhinosinusitis; mast cells; nasal polyps; recalcitrant

Mesh:

Substances:

Year:  2021        PMID: 33576238      PMCID: PMC8295225          DOI: 10.1177/0003489421995038

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.973


  31 in total

Review 1.  Endotype-driven care pathways in patients with chronic rhinosinusitis.

Authors:  Claus Bachert; Nan Zhang; Peter W Hellings; Jean Bousquet
Journal:  J Allergy Clin Immunol       Date:  2018-05       Impact factor: 10.793

2.  Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2012-04-24       Impact factor: 10.793

3.  Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps.

Authors:  Guan-Ting Zhai; Jing-Xian Li; Xin-Hao Zhang; Bo Liao; Xiang Lu; Zheng Liu
Journal:  Laryngoscope       Date:  2018-12-20       Impact factor: 3.325

Review 4.  Novel findings in immunopathophysiology of chronic rhinosinusitis and their role in a model of precision medicine.

Authors:  Xinni Xu; Yew Kwang Ong; De Yun Wang
Journal:  Allergy       Date:  2019-10-11       Impact factor: 13.146

Review 5.  Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps.

Authors:  Claus Bachert; Philippe Gevaert; Peter Hellings
Journal:  J Allergy Clin Immunol Pract       Date:  2017-05-16

6.  Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia.

Authors:  Leila Hadadi; Morteza Hafezi; Ali Akbar Amirzargar; Ramazan Ali Sharifian; Saeid Abediankenari; Hossein Asgarian-Omran
Journal:  Oncol Res Treat       Date:  2019-03-14       Impact factor: 2.825

7.  TIM-3-Expressing Mast Cells Are Present in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Erica Corredera; Binh L Phong; John A Moore; Lawrence P Kane; Stella E Lee
Journal:  Otolaryngol Head Neck Surg       Date:  2018-05-15       Impact factor: 3.497

8.  Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.

Authors:  Tanya M Laidlaw; Calman Prussin; Reynold A Panettieri; Stella Lee; Berrylin J Ferguson; Nithin D Adappa; Andrew P Lane; Marina L Palumbo; Mary Sullivan; Don Archibald; Steven I Dworetzky; Gregory T Hebrank; Michael E Bozik
Journal:  Laryngoscope       Date:  2018-10-04       Impact factor: 3.325

9.  Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps.

Authors:  Laura Van Gerven; Cristobal Langdon; Arturo Cordero; Sara Cardelús; Joaquim Mullol; Isam Alobid
Journal:  Laryngoscope       Date:  2017-11-08       Impact factor: 3.325

10.  Quantification for staging sinusitis. The Staging and Therapy Group.

Authors:  V J Lund; D W Kennedy
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1995-10
View more
  2 in total

Review 1.  Chronic Rhinosinusitis, S. aureus Biofilm and Secreted Products, Inflammatory Responses, and Disease Severity.

Authors:  Gohar Shaghayegh; Clare Cooksley; Mahnaz Ramezanpour; Peter-John Wormald; Alkis James Psaltis; Sarah Vreugde
Journal:  Biomedicines       Date:  2022-06-09

Review 2.  Nasal Cytology: A Easy Diagnostic Tool in Precision Medicine for Inflammation in Epithelial Barrier Damage in the Nose. A Perspective Mini Review.

Authors:  Cristiano Caruso; Rossana Giancaspro; Giuseppe Guida; Alberto Macchi; Massimo Landi; Enrico Heffler; Matteo Gelardi
Journal:  Front Allergy       Date:  2022-04-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.